VANCOUVER, BC, Dec. 21, 2023 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that as part of BioVaxys’ efforts to refocus on immunotherapeutics, Biovaxys and Procare Health (“Procare”) have jointly and amicably…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.